Jan 7 (Reuters) - The U.S. Food and Drug Administration said on Friday it shortened the stipulated time between the primary series of the Moderna COVID-19 vaccine and a booster dose by a month to at least five months for people aged 18 or above. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
121.9 USD | +0.68% | +9.36% | +22.56% |
May. 07 | UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating | MT |
May. 06 | News Highlights : Top Financial Services News of the Day - Monday at 4 PM ET | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B | |
+18.74% | 11.81B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- U.S. FDA cuts gap for Moderna COVID-19 booster dose to five months